<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.1.0.0 [08/02/2014 03:25:39 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, August 12, 2014 04:06:43 AM -->
<xbrli:xbrl xmlns:cycc="http://www.cyclacel.com/20140630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="cycc-20140630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_22_Jun_2009T00_00_00_TO_22_Jun_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-06-22
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jul_2009T00_00_00_TO_01_Jul_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-07-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2009T00_00_00_TO_31_Dec_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_Jan_2010T00_00_00_TO_06_Jan_2010T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-01-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2010T00_00_00_TO_02_Aug_2010T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-08-01
</xbrli:startDate>
<xbrli:endDate>
2010-08-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:March2012SaleOfCommonStockAndEconomicRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-03-01
</xbrli:startDate>
<xbrli:endDate>
2012-03-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:December2012StockIssuanceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_LegalEntityAxis_AspireCapitalFundLLCMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:December2012StockIssuanceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2013T00_00_00_TO_30_Apr_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_May_2013T00_00_00_TO_16_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:May2013SaleOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-05-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:May2013SaleOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2013T00_00_00_TO_21_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:May2013SaleOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:November2013StockIssuanceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:PurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:PurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2013-11-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:November2013StockIssuanceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2013-11-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:PurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:April2014IssuanceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-04-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:April2014IssuanceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-04-03
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2014T00_00_00_TO_22_May_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-01
</xbrli:startDate>
<xbrli:endDate>
2014-05-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2014T00_00_00_TO_30-Jun-2014T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:November2013StockIssuanceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2014-01-01</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:PurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cycc:ProductPromotionAndSaleOperationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:PurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:AspireCapitalFundLLCMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2009StockIssuanceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:July2009StockIssuanceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:January2010StockIssuanceTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:January2010StockIssuanceOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_October2010StockIssuanceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:October2010StockIssuanceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2011StockIssuanceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquityOfferingComponentsAxis">cycc:July2011StockIssuanceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_PreferredStockRedemptionPeriodAxis_PreferredStockRedemptionPeriodFromYear1November2013To31October2014Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:PreferredStockRedemptionPeriodAxis">cycc:PreferredStockRedemptionPeriodFromYear1November2013To31October2014Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_PreferredStockRedemptionPeriodAxis_PreferredStockRedemptionPeriodFromYear1November2014AndThereafterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:PreferredStockRedemptionPeriodAxis">cycc:PreferredStockRedemptionPeriodFromYear1November2014AndThereafterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2006T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_11-Aug-2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2014-08-11</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2013T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!-- 
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP6458c444c555cT{h>G97688;61;6;6186FE1EEI=16H9FG54=86=; -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>cycc:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="Country"><xbrli:measure>cycc:Country</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit>
<xbrli:unit id="Security"><xbrli:measure>cycc:Security</xbrli:measure></xbrli:unit>
<xbrli:unit id="Conversion_rate"><xbrli:measure>cycc:Conversion_rate</xbrli:measure></xbrli:unit>
<xbrli:unit id="Series"><xbrli:measure>cycc:Series</xbrli:measure></xbrli:unit>
<xbrli:unit id="Quarter"><xbrli:measure>cycc:Quarter</xbrli:measure></xbrli:unit>
<xbrli:unit id="Director"><xbrli:measure>cycc:Director</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">0001130166</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">cycc</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_11-Aug-2014T00_00_00" unitRef="shares" decimals="INF">22676475</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2014-06-30</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2014</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Q2</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">31146000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">33456000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_01_Jan_2013T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="-3">16412000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">33668000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">3388000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3422000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">639000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">639000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">403000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">403000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">35173000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">37281000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">275000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">305000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">72000</us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">24000</us-gaap:DisposalGroupIncludingDiscontinuedOperationLongLivedAssets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">35520000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">37610000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">2545000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">4543000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">4431000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3095000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">20000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">260000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">260000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">145000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">145000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">7256000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">7783000</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">7497000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">8021000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">19000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">23000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">317543000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">328774000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">-109000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-97000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">-289430000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-299111000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">28023000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">29589000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">35520000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">37610000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="0">10</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">3989749000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3989749000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_16_May_2013T00_00_00_TO_16_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_03_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">19369332</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">22676475</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">19369332</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">22676475</us-gaap:CommonStockSharesOutstanding>
<us-gaap:RevenueFromGrants contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">264000</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">476000</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">356000</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">752000</us-gaap:RevenueFromGrants>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">264000</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">476000</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">356000</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">752000</us-gaap:SalesRevenueNet>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">2631000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">4211000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">4545000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">8889000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1787000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">4470000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">1386000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">2848000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">4418000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">8681000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">5931000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">11737000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-4154000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-8205000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-5575000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-10985000</us-gaap:OperatingIncomeLoss>
<cycc:ExpenseRelatedToStockPurchaseAgreement contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:ExpenseRelatedToStockPurchaseAgreement contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:ExpenseRelatedToStockPurchaseAgreement contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">64000</cycc:ExpenseRelatedToStockPurchaseAgreement>
<cycc:ExpenseRelatedToStockPurchaseAgreement contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">111000</cycc:ExpenseRelatedToStockPurchaseAgreement>
<cycc:ChangeInValuationOfEconomicRights contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:ChangeInValuationOfEconomicRights contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-570000</cycc:ChangeInValuationOfEconomicRights>
<cycc:ChangeInValuationOfEconomicRights contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:ChangeInValuationOfEconomicRights contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">20000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">20000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-101000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">19000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-43000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-33000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InvestmentIncomeInterest contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">3000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">4000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">2000</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5500000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5504000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">26000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">26000</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5402000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">6097000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-60000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-96000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1248000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-2108000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-5635000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-11081000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-230000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-488000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-816000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-1385000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1478000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-1620000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4819000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-9696000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">24000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">50000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">10000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">23000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">10000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">10000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">20000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">20000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">3000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">8000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">8000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">14000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">14000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">30000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">30000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">7000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">7000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">15000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">15000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1492000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-1590000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4812000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-9681000</us-gaap:NetIncomeLoss>
<cycc:RedeemablePreferredStocksDividends contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:RedeemablePreferredStocksDividends contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">8366000</cycc:RedeemablePreferredStocksDividends>
<cycc:RedeemablePreferredStocksDividends contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<cycc:RedeemablePreferredStocksDividends contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>

<cycc:DividendsPreferredStocks contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">63000</cycc:DividendsPreferredStocks>
<cycc:DividendsPreferredStocks contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">185000</cycc:DividendsPreferredStocks>
<cycc:DividendsPreferredStocks contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">50000</cycc:DividendsPreferredStocks>
<cycc:DividendsPreferredStocks contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">100000</cycc:DividendsPreferredStocks>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1429000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-10141000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4862000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-9781000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1415000</cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>

<cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-10171000</cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>

<cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4869000</cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>

<cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-9796000</cycc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>

<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">13885442</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">11849270</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">22582283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">21064739</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">6638000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-3121000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4080000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">202000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-6691000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3125000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">4092000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1680000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-1643000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-4808000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-9669000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<cycc:ChangeInValuationOfLiabilitiesMeasuredAtFairValue contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1120000</cycc:ChangeInValuationOfLiabilitiesMeasuredAtFairValue>
<cycc:ChangeInValuationOfLiabilitiesMeasuredAtFairValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">20000</cycc:ChangeInValuationOfLiabilitiesMeasuredAtFairValue>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">36000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">46000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5500000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">146000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">370000</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">1124000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-34000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-1530000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">313000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-10682000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-8827000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">92000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">65000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-264000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">-192000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5500000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5672000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">127000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">22495000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">10965000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">192000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">100000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">22303000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">10865000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">-37000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">145000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
<us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">17256000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">2310000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:ProceedsFromInterestReceived contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">5000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:ProceedsFromInterestReceived contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">3000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">1811000</us-gaap:ProceedsFromIncomeTaxRefunds>
<cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">181000</cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus>
<cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0px;"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;NATURE OF OPERATIONS AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Cyclacel Pharmaceuticals,&amp;#160;Inc. (&amp;#8220;Cyclacel&amp;#8221; or &amp;#8220;the Company&amp;#8221;), a development-stage biopharmaceutical company, is a pioneer in the field of cell cycle biology with a vision to improve patient healthcare with orally available innovative medicines. Cyclacel&amp;#8217;s goal is to develop and commercialize small molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Cyclacel&amp;#8217;s clinical development priorities are focused on sapacitabine, an orally available, cell cycle modulating nucleoside analogue.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Sapacitabine is being evaluated in the SEAMLESS Phase 3 study being conducted under a Special Protocol Assessment (&amp;#8220;SPA&amp;#8221;) agreement with the US Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) for the front-line treatment of acute myeloid leukemia (&amp;#8220;AML&amp;#8221;) in the elderly and in Phase 2 studies for AML, myelodysplastic syndromes (&amp;#8220;MDS&amp;#8221;), non-small cell lung cancer (&amp;#8220;NSCLC&amp;#8221;) and chronic lymphocytic leukemia. Sapacitabine is also being evaluated in a Phase&amp;#160;1 study in combination with seliciclib, our second clinical candidate, in patients with solid tumors, in particular those carrying gBRCA mutations. The FDA and the European Medicines Agency (&amp;#8220;EMA&amp;#8221;), have designated sapacitabine as an orphan drug for the treatment of both AML and MDS.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In our second development program we are evaluating cyclin dependent kinase, or CDK, inhibitors. CDKs are involved in cancer cell growth, metastatic spread and DNA damage repair. Seliciclib, our most advanced CDK inhibitor, is an oral, highly selective inhibitor of CDK enzymes. To date, seliciclib has been evaluated in several Phase 1 and 2 studies in various cancers, including NSCLC and nasopharyngeal cancer (&amp;#8220;NPC&amp;#8221;), and has shown signs of anti-cancer activity. Seliciclib will also be evaluated in an investigator-initiated clinical study to treat rheumatoid arthritis (&amp;#8220;RA&amp;#8221;) supported by an approximately $1.5 million grant from the United Kingdom's Medical Research Council.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Our second generation CDK inhibitor, CYC065, is an oral, highly selective inhibitor of CDK enzymes. CYC065 has been shown to have increased anti-proliferative potency and improved pharmaceutical properties compared to seliciclib. Investigational new drug (&amp;#8220;IND&amp;#8221;) enabling studies with CYC065 are in progress supported by a $1.9 million grant from the Biomedical Catalyst of the United Kingdom government.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In addition to these development programs, in our polo-like kinase (&amp;#8220;PLK&amp;#8221;) inhibitor program, we have discovered CYC140 and other potent and selective small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. PLK was discovered by Professor David Glover, our Chief Scientist. We have received a grant award of approximately $3.7 million from the Biomedical Catalyst of the United Kingdom government to complete IND-directed preclinical development of CYC140.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;We currently retain virtually all marketing rights worldwide to the compounds associated with our drug programs.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As a development stage enterprise, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s existing capital resources are expected to be sufficient to take the Company beyond the completion of the SEAMLESS Phase 3 trial but not sufficient to complete development of other indications or product candidates or to commercialize any of the Company&amp;#8217;s product candidates.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The condensed consolidated balance sheet as of June 30, 2014, the condensed consolidated statements of operations, comprehensive income (loss), and cash flows for the three and six months ended June 30, 2013 and 2014 and all related disclosures contained in the accompanying notes are unaudited. The condensed consolidated balance sheet as of December&amp;#160;31, 2013 is derived from the audited consolidated financial statements included in the 2013 Annual Report on Form&amp;#160;10-K filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). The condensed consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the rules&amp;#160;and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the condensed consolidated balance sheet as of June 30, 2014, and the results of operations, comprehensive loss and cash flows for the three and six months ended June 30, 2014, have been made. The interim results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December&amp;#160;31, 2014 or for any other year. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December&amp;#160;31, 2013, included in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K filed with the SEC.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0px;"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include product returns reserve percentages and inputs used to determine stock-based compensation expense and the fair value of financial instruments and other liabilities measured at fair value. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Certain amounts in prior period financial statements have been reclassified to conform to current period financial statement presentation. On the consolidated balance sheet as of December 31, 2013, certain amounts have been reclassified from &amp;#8220;Accrued and other current liabilities&amp;#8221; to &amp;#8220;Other liabilities.&amp;#8221;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Drug candidates developed by the Company typically will require approvals or clearances from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&amp;#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was denied approval or clearance or such approval was delayed, or is unable to obtain the necessary financing to complete development and approval, there will be a material adverse impact on the Company&amp;#8217;s financial condition and results of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Cash equivalents are stated at cost, which is substantially the same as fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents and categorizes such investments as held to maturity. The objectives of the Company&amp;#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&amp;#8217;s cash flow requirements and to attain a market rate of return.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities, common stock warrants, financial instruments associated with stock purchase agreements, and other arrangements. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. The financial instruments associated with stock purchase agreements and certain other liabilities are measured at fair value using applicable inputs as described in&amp;#160;&lt;i&gt;Note 3 - Fair Value&lt;/i&gt;.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Accounting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Data management and monitoring of the Company&amp;#8217;s clinical trials are performed with the assistance of contract research organizations (&amp;#8220;CROs&amp;#8221;) or clinical research associates (&amp;#8220;CRAs&amp;#8221;) in accordance with the Company&amp;#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial. Any initial payment made to a clinical trial site is recognized upon execution of the clinical trial agreement and expensed as research and development expense.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenditures&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development expenses consist primarily of costs associated with the Company&amp;#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency and Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange gains (losses) in the statement of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company applies the accounting guidance codified in ASC 740 &amp;#8220;Income taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;) related to accounting for uncertainty in income taxes. ASC 740 specifies the accounting for uncertainty in income taxes recognized in a company&amp;#8217;s financial statements by prescribing a minimum probability threshold a tax position is required to meet before being recognized in the financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue&amp;#160;&amp;amp; Customs (&amp;#8220;HMRC&amp;#8221;), the United Kingdom&amp;#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Tax years 2011, 2012 and 2013 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the United States and the United Kingdom, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&amp;#8220;IRS&amp;#8221;), the HMRC or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Income tax benefit, net from continuing operations, on the consolidated statements of operations of $1.4 million for the six months ended June 30, 2014 consists of research and development tax credits from the HMRC.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company grants stock options, restricted stock units and restricted stock to officers, employees and directors under the Amended and Restated Equity Incentive Plan (&amp;#8220;2006 Plan&amp;#8221;), which was approved on March&amp;#160;16, 2006, as amended on May&amp;#160;21, 2007, subsequently amended and restated on April&amp;#160;14, 2008, and further amended on May 23, 2012. Under the 2006 Plan, the Company has granted various types of awards, which are described more fully in&amp;#160;&lt;i&gt;Note 6 - Stock-Based Compensation Arrangements.&lt;/i&gt;&amp;#160;The Company accounts for these awards under ASC 718&lt;i&gt;&amp;#8220;&lt;/i&gt;Compensation &amp;#8212; Stock Compensation&lt;i&gt;&amp;#8221;&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 718&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on date of grant and recognition of compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&amp;#8217;s share price, the anticipated exercise behavior of employees, interest rates, and dividend yields. These variables are projected based on historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;After considering its business activities and geographic reach, the Company has concluded that it operates in just one operating segment being the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company calculates net income (loss) per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic net income (loss) per common share was determined by dividing net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share was determined by dividing net income (loss) applicable to common shareholders by the weighted average number of shares of common stock outstanding during the period, adjusted for the dilutive effect of all potential dilutive shares outstanding during the year, which includes outstanding common stock options, restricted stock, restricted stock units, convertible preferred stock and common stock warrants.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The computation of basic earnings per share and diluted earnings per share for &amp;#8216;&amp;#8216;Income (loss) from continuing operations&amp;#8217;&amp;#8217; for the three and six months ended June 30, 2013 and 2014 is as follows (in $000s, except share and per share amounts):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 851px; text-align: left;"&gt;Net income (loss) from continuing operations&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 122px; text-align: right;"&gt;1,478&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(4,819&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(1,620&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(9,696&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Deemed dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(8,366&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(63&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(185&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(100&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Numerator for earnings per share for Income (loss) from continuing operations &amp;#8211; Basic and Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,415&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(4,869&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(10,171&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(9,796&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Weighted average shares of common stock outstanding &amp;#8211; Basic&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13,885,442&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dilutive effect of stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;41,929&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average shares of common stock outstanding - Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;13,927,371&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Basic&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and six month periods ended June 30, 2013 and 2014 as the result would be anti-dilutive:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 730px; text-align: left;"&gt;Stock options&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 152px; text-align: right;"&gt;334,996&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;487,719&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Restricted Stock and Restricted Stock Units&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Convertible preferred stock&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Common stock warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total shares excluded from calculation&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,075,507&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,228,230&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In accordance with ASC 220 &amp;#8220;Comprehensive Income&amp;#8221; (&amp;#8220;ASC 220&amp;#8221;), all components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May 22, 2014, the Board of Directors (the &amp;#8220;Board&amp;#8221;) of the Company declared a quarterly cash dividend in the amount of $0.15 per share on the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;). The cash dividend was paid on August 1, 2014 to the holders of record of the Preferred Stock as of the close of business on July 1, 2014.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Accounting Standards Adopted in the Period&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward (&amp;#8220;NOL&amp;#8221;), a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a NOL, a similar tax loss, or a tax credit carryforward, except to the extent it is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the FASB relating to certain foreign currency matters. This guidance clarifies the parent company&amp;#8217;s accounting for the cumulative translation adjustment when a reporting entity ceases to have a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity or of an investment in a foreign entity. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the FASB relating to obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date. This provides guidance for the&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, except for obligations addressed within existing guidance in GAAP. The guidance should be applied retrospectively to all prior periods presented for those obligations resulting from joint and several liability arrangements that exist at the beginning of an entity&amp;#8217;s fiscal year of adoption. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On June 10, 2014 the Company adopted guidance issued by the FASB relating to financial reporting for development stage entities. The guidance eliminates certain financial reporting requirements for development stage entities, including the presentation of inception-to-date information about income statement line items, cash flows, and equity transactions, and also eliminates an exception provided to development stage entities for determining whether an entity is a variable interest entity on the basis of the amount of equity that is at risk. The adoption of this guidance has resulted in the elimination of inception-to-date information.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the FASB issued guidance on accounting for share based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. This guidance is effective for annual periods, and interim periods within those annual periods, after January 1, 2016. We are currently evaluating the impact of the guidance on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2014, the FASB issued new guidance on accounting for revenue from contracts with customers.&amp;#160; This new guidance will replace existing revenue guidelines with a new model, in which revenue is recognized upon transfer of control over goods or services to a customer.&amp;#160; The new standard will be effective for the Company on January 1, 2017, for both interim and annual periods.&amp;#160; The guidance can be adopted using either a full retrospective (with certain practical expedients) or a modified retrospective method of transition.&amp;#160; Under the modified retrospective approach, financial statements will be prepared for the year of adoption using the new standard, but prior periods will not be adjusted. Instead, companies will recognize a cumulative catch-up adjustment to the opening balance of retained earnings at the effective date for contracts that still require performance by the company, and disclose all line items in the year of adoption as if they were prepared under current revenue requirements.&amp;#160; At this time, the Company has not decided on which method it will use to adopt the new standard, nor has it determined the effects of the new guidelines on its results of operations and financial position.&amp;#160; For the foreseeable future, the Company&amp;#8217;s revenues will be limited to grants received from government agencies or nonprofit organizations, and the Company is evaluating the effects of the new standard on these types of revenue streams.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:FairValueDisclosuresTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.38in;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;FAIR VALUE&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As defined in ASC 820, &amp;#8220;Fair Value Measurements and Disclosures&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.75in; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.75in; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its measurement of fair value.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December&amp;#160;31, 2013 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1488px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold;"&gt;ASSETS&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 715px; text-align: left;"&gt;Cash equivalents&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;26,476&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 148px; text-align: right;"&gt;26,476&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Financial instrument associated with stock&amp;#160;Purchase Agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;26,476&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;26,873&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;LIABILITIES&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Other liabilities measured at fair value:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Scottish Enterprise agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Other liabilities measured at fair value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of June 30, 2014 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1488px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold;"&gt;ASSETS&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 715px; text-align: left;"&gt;Cash equivalents&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;22,677&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 148px; text-align: right;"&gt;22,677&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Financial instrument associated with stock&amp;#160;purchase agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,677&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,963&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table reconciles the beginning and ending balances of Level 3 inputs for the six months ended June 30, 2014 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1308.67px; text-indent: -10pt; padding-left: 10pt;"&gt;Balance as of December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;20&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Change in valuation of Scottish Enterprise agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Balance as of June 30, 2014&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Financial Instrument Associated with Stock Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On November 14, 2013, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (&amp;#8220;Aspire&amp;#8221;) (the &amp;#8220;Purchase Agreement&amp;#8221;) under which Aspire purchased 511,509 shares of common stock for an aggregate purchase price of $2.0 million and committed to purchase up to an additional 3,042,038 shares from time to time as directed by the Company over the next two years at prices derived from the market prices on or near the date of each sale (see&amp;#160;&lt;i&gt;Note 8 &amp;#8211; Stockholders&amp;#8217; Equity&lt;/i&gt;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has accounted for the right to sell additional shares under the Purchase Agreement based on the guidance of ASC 815 &amp;#8220;Derivative Financial Instruments&amp;#8221; (&amp;#8220;ASC 815&amp;#8221;), which requires the instrument to be measured at fair value with changes in fair value reported in earnings. The instrument had a fair value of $0.5 million at the date of the transaction and a fair value of $0.4 million and $0.3 million as of December 31, 2013 and June 30, 2014, respectively. The $0.1 million decrease in the fair value of the Purchase Agreement during the six months ended June 30, 2014 was recognized as a loss in the consolidated statements of operations. The primary inputs used to determine fair value are the price of the Company&amp;#8217;s common stock, the remaining term, and aggregate share purchases on the measurement date. The fair value of the Purchase Agreement is remeasured each reporting period and gains or losses will continue to be reported until the agreement is exhausted or expired.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Liabilities Measured at Fair Value&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Scottish Enterprise Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On June&amp;#160;22, 2009, the Company amended the agreement with Scottish Enterprise (&amp;#8220;SE&amp;#8221;) (the &amp;#8220;Amendment&amp;#8221;), in order to allow the Company to implement a reduction of the Company&amp;#8217;s research operations located in Scotland in exchange for the parties&amp;#8217; agreement to modify the payment terms of the agreement in the principal amount of &amp;#163;5 million (approximately $8.0 million at December&amp;#160;31, 2009), which SE had previously entered into with the Company. The agreement provided for repayment of up to &amp;#163;5 million in the event the Company significantly reduced its Scottish research operations. Pursuant to the terms of the Amendment, in association with Cyclacel&amp;#8217;s material reduction in staff at its Scottish research facility, the parties agreed to a modified payment of &amp;#163;1 million (approximately $1.7 million at June&amp;#160;22, 2009) payable in two equal tranches. On July&amp;#160;1, 2009, the first installment of &amp;#163;0.5 million (approximately $0.8 million) was paid and the remaining amount of &amp;#163;0.5 million (approximately $0.8 million) was paid on January&amp;#160;6, 2010.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In addition, should a further reduction below current minimum staff levels be effectuated before July 1,&amp;#160;2014 without SE&amp;#8217;s prior consent, the Company would have been obligated to pay up to &amp;#163;4 million to SE, which will be calculated as a maximum of &amp;#163;4 million (approximately $6.5 million at December&amp;#160;31, 2013 and $6.8 million at June 30, 2014) less the market value of the shares held by SE at the time staffing levels in Scotland fall below the prescribed minimum levels. If the Company were to have reduced staffing levels below the prescribed levels, the amount potentially payable to SE would have been approximately &amp;#163;3.8 million (approximately $6.3 million) and approximately &amp;#163;3.9 million (approximately $6.6 million) at December&amp;#160;31, 2013 and June 30, 2014, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;This arrangement is accounted for as a liability under ASC Topic 480 &amp;#8220;Distinguishing Liabilities from Equity&amp;#8221; (&amp;#8220;ASC 480&amp;#8221;), and is measured at fair value. Changes in fair value are recognized in earnings. Due to the nature of the associated contingency and the likelihood of occurrence, the Company concluded the fair value of this liability was approximately $20,000 and $0 at December&amp;#160;31, 2013 and June 30, 2014, respectively. The most significant inputs in estimating the fair value of this liability are the probabilities that staffing levels fall below the prescribed minimum and that the Company is unable or unwilling to replace such employees within the prescribed time period. At December&amp;#160;31, 2013, the Company used a scenario analysis model to arrive at the fair value of the Scottish Enterprise Agreement and assumed a 30% probability of falling below a minimum staffing level and a 1% probability that the occurrence of such an event would not be cured within the prescribed time period. At June 30, 2014, the Company determined that the probability of falling below a minimum staffing level was 0% given the proximity to the expiration of the agreement on July 1, 2014 and staffing levels had not fallen below the minimum level as of that date. Changes in the value of this liability have been recorded in the consolidated statement of operations.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
<cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of prepaid expenses and other current assets at December&amp;#160;31, 2013 and June 30, 2014 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 965.76px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Research and development tax credit receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 132.72px; text-align: right;"&gt;1,744&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 131.81px; text-align: right;"&gt;1,374&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Prepayments&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;427&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;1,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Grant receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;357&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;202&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Sales tax receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;209&lt;/td&gt;
&lt;td style="font: 10pt/normal
 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;378&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;Deposits&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;132&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;128&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Other current assets&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;519&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;325&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,388&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,422&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0px;"&gt;&lt;/td&gt;
&lt;td style="width: 27.35pt;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;ACCRUED AND OTHER CURRENT LIABILITIES&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Accrued and other current liabilities consisted of the following (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1457px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1065.67px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Accrued research and development&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 146px; text-align: right;"&gt;3,435&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 145px; text-align: right;"&gt;2,761&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Accrued legal and professional fees&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;265&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;183&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Other current liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;731&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;151&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;4,431&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,095&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;STOCK BASED COMPENSATION&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding), vest ratably over three to four years. Certain awards made to executive officers vest over three to five years, depending on the terms of their employment with the Company.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes all share-based awards under the straight-line attribution method. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company evaluates its forfeiture assumptions quarterly and the expected forfeiture rate is adjusted when necessary. Ultimately, the actual expense recognized over the vesting period is based on only those shares that vest.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three and six months ended June 30, 2013 and 2014 as shown in the following table (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size:
 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 688.18px; text-align: left;"&gt;General and administrative&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 119.09px; text-align: right;"&gt;60&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 119.09px; text-align: right;"&gt;126&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 118.18px; text-align: right;"&gt;117&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 118.18px; text-align: right;"&gt;255&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;Research and development&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;14&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;57&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;29&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;115&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;Stock-based compensation costs before income taxes&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;74&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;183&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;146&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black;
 border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;370&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;2006 Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On March&amp;#160;16, 2006, the 2006 Plan was adopted, under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The Company has reserved 1,428,571 shares of the Company&amp;#8217;s common stock under the 2006 Plan. Stock option awards granted under the 2006 Plan have a maximum life of 10 years and generally vest over a four-year period from the date of grant.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;There were 32,697 and 54,000 options granted during the six months ended June 30, 2013 and 2014, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;There were no stock options exercised during the three and six months ended June 30, 2013 and 2014. The Company does not expect to be able to benefit for the deduction for stock option exercises that may occur during the year ended December 31, 2014 because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income for the year ended December 31, 2014.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Outstanding Options&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of the share option activity and related information is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1351.81px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Number&amp;#160;of&lt;br /&gt;Options&lt;br /&gt;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price Per Share&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term&amp;#160;(Years)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&amp;#160;($000)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size:
 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 582.13px; text-indent: -10pt; padding-left: 10pt;"&gt;Options outstanding at December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;949,685&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;15.02&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;7.38&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 148.18px; text-align: right;"&gt;152&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;54,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;3.09&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Cancelled/forfeited&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(2,387&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;31.08&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Options outstanding at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font:
 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;14.34&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;7.05&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;8&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Unvested at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;487,253&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;4.23&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;9.37&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Vested and exercisable at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;514,045&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;23.92&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;4.85&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;6&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Estimates of pre-vesting option
 forfeitures are based on the Company&amp;#8217;s experience. Currently the Company uses a forfeiture rate of 0 - 30% depending on when and to whom the options are granted. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and may impact the amount of compensation expense to be recognized in future periods.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Summarized information for restricted stock unit activity for the six months ended June 30, 2014 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif;"&gt;&lt;b&gt;Restricted&amp;#160;Stock&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt;"&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Units&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&amp;#160;Average&lt;br /&gt;Grant&lt;br /&gt;Date&amp;#160;Value&amp;#160;Per&amp;#160;Share&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 833.94px; text-indent: -10pt; padding-left: 10pt;"&gt;Non-vested at December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 199.09px; text-align: right;"&gt;119,248&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 198.18px; text-align: right;"&gt;5.62&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(233&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;5.39&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Non-vested at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;119,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;5.62&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;div align="left" style="font: 13.63px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; margin-left: 0.5in; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="width: 412.52px; font-size: 1pt; border-top-color: black; border-top-width: 1pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(1)&lt;/td&gt;
&lt;td&gt;Includes 85,097 restricted stock units issued that will vest upon the fulfillment of certain clinical and financial conditions.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 13.63px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company issued 85,097 restricted stock units to employees during the three months ended June 30, 2013 that will vest upon the fulfillment of certain clinical and financial conditions and will terminate if they have not vested by December 31, 2014. The Company determined that the satisfaction of the vesting criteria was not probable as of June 30, 2014 and, as a result, did not record any expense related to these awards for the three and six months ended June 30, 2014. The Company did not issue any restricted stock units during the six months ended June 30, 2014.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.38in;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Distribution, Licensing and Research Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of products employing the technology or falling under claims of patent applications.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&amp;#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee, Phase 3 entry milestone, and certain past reimbursements have been paid. A further $10.0 million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones and the Company&amp;#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal, with the right of first refusal ending sixty days after notification, to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on nine months&amp;#8217; notice, or twelve months&amp;#8217; notice, if after a launch of a sapacitabine-based product, or by either party for material default.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0px;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As of June 30, 2014, there were 335,273 shares of the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;) issued and outstanding at an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August&amp;#160;and November, commencing February&amp;#160;1, 2005. Any dividends must be declared by the Company&amp;#8217;s Board and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $10.00 per share, plus accrued and unpaid dividends.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Preferred Stock is convertible at the option of the holder at any time into the Company&amp;#8217;s shares of common stock at a conversion rate of approximately 0.06079 shares of common stock for each share of Preferred Stock based on a price of $164.50. The Company has reserved 20,381 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at June 30, 2014. The shares of previously-converted Preferred Stock have been retired, cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board as shares of Preferred Stock of one or more series.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&amp;#8217;s common stock has exceeded $246.75, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Board. This right accrued to the holders of Preferred Stock as of August&amp;#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&amp;#160;24, 2011.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption prices per share stated below, plus an amount equal to accrued and unpaid dividends up to the date of redemption:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1175px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 927.67px; text-indent: -10pt; padding-left: 10pt;"&gt;Year from November&amp;#160;1, 2013 to October&amp;#160;31, 2014&lt;/td&gt;
&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 199px; text-align: right;"&gt;10.06&lt;/td&gt;
&lt;td style="width: 11px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt;"&gt;November&amp;#160;1, 2014 and thereafter&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&amp;#160;1, 2005 (the &amp;#8220;Exchange Date&amp;#8221;) for the Company&amp;#8217;s 6% Convertible Subordinated Debentures (&amp;#8220;Debentures&amp;#8221;) at the rate of $10.00 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have terms substantially similar to those of the Preferred Stock. No such exchanges have taken place to date.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Conversion of Convertible Preferred Stock&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During the six months ended June 30, 2013, the Company converted an aggregate of 792,460 shares of Preferred Stock into an aggregate of 1,513,653 shares of the Company&amp;#8217;s common stock. There were no conversions of the Company&amp;#8217;s Preferred Stock into shares of common stock during the six months ended June 30, 2014. Since the Company&amp;#8217;s transaction with Xcyte Therapies,&amp;#160;Inc. in 2006, holders have exchanged 1,711,540 shares of Preferred Stock into common stock as a result of arms-length negotiations between the Company and the other parties.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below provides details of the aggregate activities during the six months ended June 30, 2013:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1378px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&lt;br  /&gt;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;br  /&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1185.67px; text-indent: -10pt; padding-left: 10pt;"&gt;Preferred shares exchanged&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 138px; text-align: right;"&gt;792,460&lt;/td&gt;
&lt;td style="width: 13px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt;"&gt;Shares of common stock issued:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;At stated conversion terms&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;48,174&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Incremental shares issued under the exchange transaction&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,465,479&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Total shares of common stock issued&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,513,653&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As the Preferred stockholders received additional shares of common stock issued to them upon conversion as compared to what they would have been entitled to receive under the stated rate of exchange, the Company recorded the excess of (1)&amp;#160;the fair value of all securities and other consideration transferred to the holders of the Preferred Stock and (2)&amp;#160;the fair value of securities issuable pursuant to the original conversion terms as a deemed dividend resulting in an increase in the net loss attributable to common shareholders. Specifically, the Company recorded deemed dividends related to the additional shares issued under the exchange transactions of $8.4 million for the six months ended June 30, 2013.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;April&amp;#160;2014 Underwriting Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On April&amp;#160;3, 2014, the Company entered into an underwriting agreement relating to the public offering and sale of 2,857,143 shares of the Company&amp;#8217;s common stock, par value $0.001, at a price to the public of $3.50 per share, for proceeds, net of certain fees and expenses, of approximately $9.3 million.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;November&amp;#160;2013 Stock Purchase Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On November 14, 2013, the Company entered into a common stock Purchase Agreement with Aspire. Upon execution of the Purchase Agreement, Aspire purchased 511,509 shares of common stock for an aggregate purchase price of $2.0 million. Under the terms of the Purchase Agreement, Aspire has committed to purchase up to an additional 3,042,038 shares from time to time as directed by the Company or, in certain instances, as agreed to by both parties, over the next two years at prices derived from the market prices on or near the date of each sale. However, such commitment is limited to an additional $18.0 million of share purchases. In consideration for entering into the Purchase Agreement, concurrent with the execution of the Purchase Agreement, the Company issued 166,105 shares of the Company&amp;#8217;s common stock to Aspire in lieu of a commitment fee. The fair value of these shares has been recorded as a component of other assets and will continue to be remeasured each reporting period, until the agreement is exhausted or expired, with gains or losses reported in the consolidated statements of operations. During the six months ended June 30, 2014, the Company sold 450,000 shares to Aspire under the Purchase Agreement for proceeds of $1.7 million.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;May&amp;#160;2013 Underwriting Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May&amp;#160;16, 2013, the Company entered into an underwriting agreement relating to the public offering and sale of up to 6,666,667 shares of the Company&amp;#8217;s common stock, par value $0.001, at a price to the public of $3.00 per share. On May&amp;#160;21, 2013, the Company closed the public offering and completed the sale of 6,833,334 shares of its common stock, which includes 166,667 shares that were subject to the underwriters&amp;#8217; over-allotment option, at a price to the public of $3.00 per share, for proceeds, net of certain fees and expenses, of approximately $19.0 million.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Common Stock Bonus&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During the six months ended June 30, 2013, the Company issued 31,643 shares of common stock with a fair value of approximately $0.2 million to employees in lieu of cash in connection with bonuses recorded for the year ended December&amp;#160;31, 2012. There were no such stock issuances during the six months ended June 30, 2014.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;December&amp;#160;2012 Stock Purchase Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On December&amp;#160;14, 2012, the Company entered into a common stock purchase agreement with Aspire. Upon execution of the purchase agreement, Aspire purchased 158,982 shares of common stock for an aggregate purchase price of $1.0 million based on the closing price of the Company&amp;#8217;s common stock on December&amp;#160;13, 2012, the date upon which the business terms were agreed. Under the terms of the purchase agreement, Aspire committed to purchase up to an additional 1,455,787 shares from time to time as directed by the Company over the next two years at prices derived from the market prices on or near the date of each sale. However, such commitment was limited to an additional $19.0 million of share purchases. In consideration for entering into the Purchase Agreement, concurrent with the execution of the Purchase Agreement, the Company issued 74,548 shares of the Company&amp;#8217;s common stock to Aspire in lieu of a commitment fee. The fair value of the 74,548 shares of common stock along with the direct costs incurred in the connection with the Aspire transaction have been allocated to the shares sold at inception of this agreement and the right to sell additional shares in the future based on the ratio of shares sold at inception to the listed shares subject to this agreement. The agreement terminated on November 14, 2013 and no rights or obligations remain under the agreement.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;March&amp;#160;2012 Sale of Common Stock and Economic Rights&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On March&amp;#160;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders, raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing were used to fund ongoing litigation-related expenses on certain intellectual property and for general corporate purposes. Under the terms of the purchase agreement, the investors purchased 669,726 shares of the Company&amp;#8217;s common stock at a price of $4.53, which is equal to the 10-day average closing price of the Company&amp;#8217;s common stock for the period ending on March&amp;#160;21, 2012. The shares issued at closing were subject to a lock-up period of one year from the date of issuance.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap. In April 2013, the Economic Rights were settled for payment of $0.6 million.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table summarizes information about warrants outstanding at June 30, 2014:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Issued&amp;#160;in&amp;#160;Connection&amp;#160;With&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Expiration&lt;/font&gt;&lt;br  /&gt;&lt;font style="font-size: 8pt;"&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Common&lt;br  /&gt;Shares&lt;br  /&gt;Issuable&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br  /&gt;Average&lt;br  /&gt;Exercise&lt;br  /&gt;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 942.67px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;July&amp;#160;2009 Series&amp;#160;II stock issuance&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 157px; text-align: center;"&gt;2014&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 157px; text-align: right;"&gt;98,893&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 156px; text-align: right;"&gt;7.00&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt;"&gt;January&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;101,785&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;22.82&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt;"&gt;January&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100,714&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;19.95&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt;"&gt;October&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;594,513&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13.44&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;July&amp;#160;2011 stock issuance&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;2016&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;544,117&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;9.52&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,440,022&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;12.63&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;There were no exercises of warrants during the six months ended June 30, 2013 and 2014. Warrants for 151,773 shares of common stock, issued in connection with the February 2007 stock issuance, expired during the six months ended June 30, 2014.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.35in;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;DISCONTINUED OPERATIONS&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 0.5in;"&gt;On August&amp;#160;10, 2012, the Company entered into an agreement with Sinclair Pharmaceuticals Limited (&amp;#8220;Sinclair&amp;#8221;) to terminate, effective September&amp;#160;30, 2012, the distribution agreements relating to the promotion and sale of Xclair&amp;#174;, Numoisyn&amp;#174; Lozenges and Numoisyn&amp;#174; Liquid (collectively, the &amp;#8220;ALIGN products&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 0.5in;"&gt;Product revenue, cost of goods sold and selling, general and administrative costs related to the promotion and sale of the ALIGN products have been reclassified from operating results from continuing operations to income from discontinued operations in the consolidated statement of operations for all periods presented as follows (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1422.72px; border-collapse: collapse;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 726.67px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Interest income&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;50&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 127.27px; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent:
 -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Income tax on discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(10&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(3&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(20&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(8&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Net income from discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;14&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;7&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;30&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;15&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 38.9pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 38.9pt;"&gt;The assets and liabilities associated with product promotion and sales have been classified within assets and liabilities of discontinued operations in the accompanying consolidated balance sheets (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-indent: 38.9pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 1422.72px; border-collapse: collapse;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;br /&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;br /&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Current assets of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1026.97px; text-align: left; text-indent: -10pt; padding-left: 20pt;"&gt;Short term portion of minimum royalty arrangement receivable, net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142.72px; text-align: right;"&gt;379&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141.81px; text-align: right;"&gt;258&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Returns indemnification receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;145&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Total current assets of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;639&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;403&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Long-term assets of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Long-term portion of minimum royalty arrangement receivable, net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;72&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;24&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt;
 padding-left: 20pt;"&gt;Total assets of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;711&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;427&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Current liabilities of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Returns provision&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;145&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: -10pt; letter-spacing: normal; padding-bottom: 2.5pt; padding-left: 20pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Total current liabilities of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 2.5pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 2.5pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 2.5pt; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;145&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>

<us-gaap:UseOfEstimates contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include product returns reserve percentages and inputs used to determine stock-based compensation expense and the fair value of financial instruments and other liabilities measured at fair value. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
<cycc:RisksAndUncertaintiesPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Drug candidates developed by the Company typically will require approvals or clearances from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&amp;#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was denied approval or clearance or such approval was delayed, or is unable to obtain the necessary financing to complete development and approval, there will be a material adverse impact on the Company&amp;#8217;s financial condition and results of operations.&lt;/div&gt;
&lt;/div&gt;</cycc:RisksAndUncertaintiesPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Cash equivalents are stated at cost, which is substantially the same as fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents and categorizes such investments as held to maturity. The objectives of the Company&amp;#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&amp;#8217;s cash flow requirements and to attain a market rate of return.&lt;/div&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities, common stock warrants, financial instruments associated with stock purchase agreements, and other arrangements. The carrying amounts of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. The financial instruments associated with stock purchase agreements and certain other liabilities are measured at fair value using applicable inputs as described in&amp;#160;&lt;i&gt;Note 3 - Fair Value&lt;/i&gt;.&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.&lt;/div&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<cycc:ClinicalTrialAccountingPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Accounting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Data management and monitoring of the Company&amp;#8217;s clinical trials are performed with the assistance of contract research organizations (&amp;#8220;CROs&amp;#8221;) or clinical research associates (&amp;#8220;CRAs&amp;#8221;) in accordance with the Company&amp;#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial. Any initial payment made to a clinical trial site is recognized upon execution of the clinical trial agreement and expensed as research and development expense.&lt;/p&gt;</cycc:ClinicalTrialAccountingPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenditures&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development expenses consist primarily of costs associated with the Company&amp;#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.&lt;/div&gt;
&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency and Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange gains (losses) in the statement of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.&lt;/div&gt;
&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company applies the accounting guidance codified in ASC 740 &amp;#8220;Income taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;) related to accounting for uncertainty in income taxes. ASC 740 specifies the accounting for uncertainty in income taxes recognized in a company&amp;#8217;s financial statements by prescribing a minimum probability threshold a tax position is required to meet before being recognized in the financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue&amp;#160;&amp;amp; Customs (&amp;#8220;HMRC&amp;#8221;), the United Kingdom&amp;#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Tax years 2011, 2012 and 2013 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the United States and the United Kingdom, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&amp;#8220;IRS&amp;#8221;), the HMRC or state tax authorities if they have or will be used in a future period. The Company is currently not under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Income tax benefit, net from continuing operations, on the consolidated statements of operations of $1.4 million for the six months ended June 30, 2014 consists of research and development tax credits from the HMRC.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company grants stock options, restricted stock units and restricted stock to officers, employees and directors under the Amended and Restated Equity Incentive Plan (&amp;#8220;2006 Plan&amp;#8221;), which was approved on March&amp;#160;16, 2006, as amended on May&amp;#160;21, 2007, subsequently amended and restated on April&amp;#160;14, 2008, and further amended on May 23, 2012. Under the 2006 Plan, the Company has granted various types of awards, which are described more fully in&amp;#160;&lt;i&gt;Note 6 - Stock-Based Compensation Arrangements.&lt;/i&gt;&amp;#160;The Company accounts for these awards under ASC 718&amp;#160;&lt;i&gt;&amp;#8220;&lt;/i&gt;Compensation &amp;#8212; Stock Compensation&lt;i&gt;&amp;#8221;&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 718&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on date of grant and recognition of compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&amp;#8217;s share price, the anticipated exercise behavior of employees, interest rates, and dividend yields. These variables are projected based on historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates.&lt;/div&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;After considering its business activities and geographic reach, the Company has concluded that it operates in just one operating segment being the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom.&lt;/div&gt;
&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company calculates net income (loss) per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic net income (loss) per common share was determined by dividing net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share was determined by dividing net income (loss) applicable to common shareholders by the weighted average number of shares of common stock outstanding during the period, adjusted for the dilutive effect of all potential dilutive shares outstanding during the year, which includes outstanding common stock options, restricted stock, restricted stock units, convertible preferred stock and common stock warrants.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The computation of basic earnings per share and diluted earnings per share for &amp;#8216;&amp;#8216;Income (loss) from continuing operations&amp;#8217;&amp;#8217; for the three and six months ended June 30, 2013 and 2014 is as follows (in $000s, except share and per share amounts):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 851px; text-align: left;"&gt;Net income (loss) from continuing operations&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 122px; text-align: right;"&gt;1,478&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(4,819&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(1,620&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(9,696&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Deemed dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(8,366&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(63&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(185&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(100&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Numerator for earnings per share for Income (loss) from continuing operations &amp;#8211; Basic and Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,415&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(4,869&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(10,171&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(9,796&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Weighted average shares of common stock outstanding &amp;#8211; Basic&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13,885,442&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dilutive effect of stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;41,929&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average shares of common stock outstanding - Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;13,927,371&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Basic&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three and six month periods ended June 30, 2013 and 2014 as the result would be anti-dilutive:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 730px; text-align: left;"&gt;Stock options&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 152px; text-align: right;"&gt;334,996&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;487,719&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 151px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Restricted Stock and Restricted Stock Units&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Convertible preferred stock&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Common stock warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total shares excluded from calculation&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,075,507&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,228,230&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In accordance with ASC 220 &amp;#8220;Comprehensive Income&amp;#8221; (&amp;#8220;ASC 220&amp;#8221;), all components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income.&lt;/div&gt;
&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<cycc:RecentEventPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May 22, 2014, the Board of Directors (the &amp;#8220;Board&amp;#8221;) of the Company declared a quarterly cash dividend in the amount of $0.15 per share on the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;). The cash dividend was paid on August 1, 2014 to the holders of record of the Preferred Stock as of the close of business on July 1, 2014.&lt;/div&gt;
&lt;/div&gt;</cycc:RecentEventPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Accounting Standards Adopted in the Period&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward (&amp;#8220;NOL&amp;#8221;), a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a NOL, a similar tax loss, or a tax credit carryforward, except to the extent it is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the FASB relating to certain foreign currency matters. This guidance clarifies the parent company&amp;#8217;s accounting for the cumulative translation adjustment when a reporting entity ceases to have a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity or of an investment in a foreign entity. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On January 1, 2014 the Company adopted guidance issued by the FASB relating to obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date. This provides guidance for the&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, except for obligations addressed within existing guidance in GAAP. The guidance should be applied retrospectively to all prior periods presented for those obligations resulting from joint and several liability arrangements that exist at the beginning of an entity&amp;#8217;s fiscal year of adoption. The adoption of this guidance has not had a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On June 10, 2014 the Company adopted guidance issued by the FASB relating to financial reporting for development stage entities. The guidance eliminates certain financial reporting requirements for development stage entities, including the presentation of inception-to-date information about income statement line items, cash flows, and equity transactions, and also eliminates an exception provided to development stage entities for determining whether an entity is a variable interest entity on the basis of the amount of equity that is at risk. The adoption of this guidance has resulted in the elimination of inception-to-date information.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the FASB issued guidance on accounting for share based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. This guidance is effective for annual periods, and interim periods within those annual periods, after January 1, 2016. We are currently evaluating the impact of the guidance on our consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2014, the FASB issued new guidance on accounting for revenue from contracts with customers.&amp;#160; This new guidance will replace existing revenue guidelines with a new model, in which revenue is recognized upon transfer of control over goods or services to a customer.&amp;#160; The new standard will be effective for the Company on January 1, 2017, for both interim and annual periods.&amp;#160; The guidance can be adopted using either a full retrospective (with certain practical expedients) or a modified retrospective method of transition.&amp;#160; Under the modified retrospective approach, financial statements will be prepared for the year of adoption using the new standard, but prior periods will not be adjusted. Instead, companies will recognize a cumulative catch-up adjustment to the opening balance of retained earnings at the effective date for contracts that still require performance by the company, and disclose all line items in the year of adoption as if they were prepared under current revenue requirements.&amp;#160; At this time, the Company has not decided on which method it will use to adopt the new standard, nor has it determined the effects of the new guidelines on its results of operations and financial position.&amp;#160; For the foreseeable future, the Company&amp;#8217;s revenues will be limited to grants received from government agencies or nonprofit organizations, and the Company is evaluating the effects of the new standard on these types of revenue streams.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 0.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;br /&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 0.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;br /&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 0.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 0.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;
&lt;td style="font: bold 8pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 740px; text-align: left;"&gt;Stock options&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;334,996&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;487,719&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 127.27px; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;Restricted Stock and Restricted Stock Units&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font:
 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;123,143&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;119,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;Convertible preferred stock&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;25,573&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;20,381&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;Common stock warrants&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,591,795&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,440,022&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;Total shares excluded from calculation&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,075,507&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,228,230&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;2,580,716&lt;/td&gt;
&lt;td style="font:
 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December&amp;#160;31, 2013 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1488px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold;"&gt;ASSETS&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 715px; text-align: left;"&gt;Cash equivalents&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;26,476&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 148px; text-align: right;"&gt;26,476&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Financial instrument associated with stock&amp;#160;Purchase Agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;26,476&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;397&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;26,873&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;LIABILITIES&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Other liabilities measured at fair value:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Scottish Enterprise agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Other liabilities measured at fair value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of June 30, 2014 (in $000s):&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1488px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-weight: bold;"&gt;ASSETS&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 715px; text-align: left;"&gt;Cash equivalents&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;22,677&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 149px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 148px; text-align: right;"&gt;22,677&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Financial instrument associated with stock&amp;#160;purchase agreement&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,677&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,963&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 965.76px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Research and development tax credit receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 132.72px; text-align: right;"&gt;1,744&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 131.81px; text-align: right;"&gt;1,374&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Prepayments&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;427&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;1,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Grant receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;357&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;202&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Sales tax receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;209&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;378&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;Deposits&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;132&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;128&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr
 style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Other current assets&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;519&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;325&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,388&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,422&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1457px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1065.67px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Accrued research and development&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 146px; text-align: right;"&gt;3,435&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 145px; text-align: right;"&gt;2,761&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Accrued legal and professional fees&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;265&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;183&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Other current liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;731&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;151&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;4,431&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;3,095&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 688.18px; text-align: left;"&gt;General and administrative&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 119.09px; text-align: right;"&gt;60&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 119.09px; text-align: right;"&gt;126&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 118.18px; text-align: right;"&gt;117&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 118.18px; text-align: right;"&gt;255&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;Research and development&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;14&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;57&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman',
 times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;29&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;115&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;Stock-based compensation costs before income taxes&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;74&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;183&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;146&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;370&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1351.81px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Number&amp;#160;of&lt;br /&gt;Options&lt;br /&gt;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price Per Share&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term&amp;#160;(Years)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&amp;#160;($000)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 582.13px; text-indent: -10pt; padding-left: 10pt;"&gt;Options outstanding at December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;949,685&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;15.02&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 149.09px; text-align: right;"&gt;7.38&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 148.18px; text-align: right;"&gt;152&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;54,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;3.09&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Cancelled/forfeited&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(2,387&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;31.08&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Options outstanding at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;1,001,298&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;14.34&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;7.05&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;8&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Unvested at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;487,253&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;4.23&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;9.37&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Vested and exercisable at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;514,045&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;23.92&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom:
 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;4.85&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;6&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.25in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif;"&gt;&lt;b&gt;Restricted&amp;#160;Stock&lt;/b&gt;&lt;/font&gt;&lt;font style="font-size: 8pt;"&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Units&amp;#160;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&amp;#160;Average&lt;br /&gt;Grant&lt;br /&gt;Date&amp;#160;Value&amp;#160;Per&amp;#160;Share&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 833.94px; text-indent: -10pt; padding-left: 10pt;"&gt;Non-vested at December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 199.09px; text-align: right;"&gt;119,248&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 198.18px; text-align: right;"&gt;5.62&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(233&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;5.39&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Non-vested at June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;119,015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;5.62&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;div align="left" style="font: 13.63px/normal 'times new roman', times, serif; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; margin-left: 0.5in; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="width: 412.52px; font-size: 1pt; border-top-color: black; border-top-width: 1pt; border-top-style: solid;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(1)&lt;/td&gt;
&lt;td&gt;Includes 85,097 restricted stock units issued that will vest upon the fulfillment of certain clinical and financial conditions.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<cycc:ScheduleOfPreferredStockRedemptionPricesTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="width: 1067.27px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top; background-color: #cceeff;"&gt;
&lt;td style="width: 897.27px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Year from November&amp;#160;1, 2013 to October&amp;#160;31, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10.9px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10.9px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 138.18px; text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;10.06&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; background-color: white;"&gt;
&lt;td&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;November&amp;#160;1, 2014 and thereafter&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;10.00&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;</cycc:ScheduleOfPreferredStockRedemptionPricesTableTextBlock>
<us-gaap:ScheduleOfConversionsOfStockTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1322.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Six&lt;br /&gt;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;br /&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1137.58px; text-indent: -10pt; padding-left: 10pt;"&gt;Preferred shares exchanged&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 131.81px; text-align: right;"&gt;792,460&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 12.72px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;Shares of common stock issued:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;At stated conversion terms&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;48,174&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Incremental shares issued under the exchange transaction&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;1,465,479&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Total shares of common stock issued&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,513,653&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfConversionsOfStockTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;Issued&amp;#160;in&amp;#160;Connection&amp;#160;With&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font style="font-size: 8pt;"&gt;Expiration&lt;br /&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Common&lt;br /&gt;Shares&lt;br /&gt;Issuable&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 854.85px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;July&amp;#160;2009 Series&amp;#160;II stock issuance&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 170.9px; text-align: center;"&gt;2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142.72px; text-align: right;"&gt;98,893&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141.81px; text-align: right;"&gt;7.00&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;January&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;101,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;22.82&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;January&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;100,714&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;19.95&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt;"&gt;October&amp;#160;2010 stock issuance&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center;"&gt;2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;594,513&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;"&gt;13.44&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;July&amp;#160;2011 stock issuance&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1pt;"&gt;2016&lt;/td&gt;
&lt;td style="font: 10pt/normal
 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;544,117&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 1pt;"&gt;9.52&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,440,022&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; padding-bottom: 2.5pt;"&gt;12.63&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 726.67px; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Interest income&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 128.18px; text-align: right;"&gt;50&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 127.27px; text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Income tax on discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(10&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(3&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif;
 text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(20&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(8&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Net income from discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;14&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;7&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;30&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;15&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 38.9pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;December&amp;#160;31,&lt;br /&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;June 30,&lt;br /&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Current assets of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1026.97px; text-align: left; text-indent: -10pt; padding-left: 20pt;"&gt;Short term portion of minimum royalty arrangement receivable, net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 14.54px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142.72px; text-align: right;"&gt;379&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman',
 times, serif; width: 14.54px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141.81px; text-align: right;"&gt;258&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Returns indemnification receivable&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;145&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Total current assets of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;639&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;403&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Long-term assets of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Long-term portion of minimum royalty arrangement receivable, net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;72&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;24&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 20pt;"&gt;Total assets of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;711&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;427&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 10pt;"&gt;Current liabilities of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 20pt;"&gt;Returns provision&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;145&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 20pt;"&gt;Total current liabilities of discontinued operations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;260&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;145&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
<cycc:GrantsAwardedByMedicalResearchCouncil contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-5">1500000</cycc:GrantsAwardedByMedicalResearchCouncil>
<us-gaap:ProceedsFromGrantors contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-5">1900000</us-gaap:ProceedsFromGrantors>
<cycc:ProceedsFromGrantors2 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-5">3700000</cycc:ProceedsFromGrantors2>
<us-gaap:NumberOfOperatingSegments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
<us-gaap:NumberOfCountriesInWhichEntityOperates contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="Country" decimals="INF">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
<us-gaap:PreferredStockDividendsPerShareDeclared contextRef="Context_Custom_01_May_2014T00_00_00_TO_22_May_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:PreferredStockDividendsPerShareDeclared>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_Custom_01_May_2014T00_00_00_TO_22_May_2014T00_00_00" unitRef="pure" decimals="2">0.06</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">0.06</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">2075507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">334996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">25573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1591795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0">123143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">2228230</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">487719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">25573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1591795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0">123143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">2580716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1001298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">20381</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1440022</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0">119015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">2580716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1001298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">20381</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1440022</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0">119015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">26476000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">26476000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">22677000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">22677000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">397000</cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">397000</cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">286000</cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">286000</cycc:FinancialInstrumentAssociatedWithStockPurchaseAgreementFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">26476000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">26873000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">397000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">22677000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">22963000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">286000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="0">20000</us-gaap:GuaranteesFairValueDisclosure>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">20000</us-gaap:GuaranteesFairValueDisclosure>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">20000</us-gaap:GuaranteesFairValueDisclosure>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:GuaranteesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="0">0</us-gaap:GuaranteesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">20000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">20000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">20000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">20000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="Context_Custom_01_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_LegalEntityAxis_AspireCapitalFundLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">158982</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">511509</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">511509</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="Context_6ME_01-Jan-2014T00_00_00_TO_30-Jun-2014T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">450000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
<us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="Context_Custom_01_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_LegalEntityAxis_AspireCapitalFundLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-6">1000000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
<us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">2000000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
<us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-6">2000000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
<us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="Context_6ME_01-Jan-2014T00_00_00_TO_30-Jun-2014T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">1700000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
<cycc:CommonStockPurchaseAgreementShares contextRef="Context_As_Of_14_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">1455787</cycc:CommonStockPurchaseAgreementShares>
<cycc:CommonStockPurchaseAgreementShares contextRef="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">3042038</cycc:CommonStockPurchaseAgreementShares>
<cycc:CommonStockPurchaseAgreementShares contextRef="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">3042038</cycc:CommonStockPurchaseAgreementShares>
<cycc:CommonStockPurchaseAgreementTermPeriod contextRef="Context_Custom_01_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_LegalEntityAxis_AspireCapitalFundLLCMember_StatementEquityComponentsAxis_CommonStockMember">P2Y</cycc:CommonStockPurchaseAgreementTermPeriod>
<cycc:CommonStockPurchaseAgreementTermPeriod contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember">P2Y</cycc:CommonStockPurchaseAgreementTermPeriod>
<cycc:CommonStockPurchaseAgreementTermPeriod contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember">P2Y</cycc:CommonStockPurchaseAgreementTermPeriod>
<us-gaap:ReceivablesFairValueDisclosure contextRef="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">500000</us-gaap:ReceivablesFairValueDisclosure>
<us-gaap:ReceivablesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">400000</us-gaap:ReceivablesFairValueDisclosure>
<us-gaap:ReceivablesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">300000</us-gaap:ReceivablesFairValueDisclosure>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PurchaseAgreementMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-5">100000</us-gaap:DerivativeGainLossOnDerivativeNet>
<cycc:FinancingAgreementAmountToBePaidAsPercentageOfFutureLitigationSettlementReceived contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember" unitRef="pure" decimals="2">0.10</cycc:FinancingAgreementAmountToBePaidAsPercentageOfFutureLitigationSettlementReceived>
<us-gaap:GuaranteeObligationsMaximumExposure contextRef="Context_As_Of_22_Jun_2009T00_00_00_TO_22_Jun_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-6">5000000</us-gaap:GuaranteeObligationsMaximumExposure>
<us-gaap:GuaranteeObligationsMaximumExposure contextRef="Context_As_Of_31_Dec_2009T00_00_00_TO_31_Dec_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-6">8000000</us-gaap:GuaranteeObligationsMaximumExposure>
<us-gaap:GuaranteeObligationsMaximumExposure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">6500000</us-gaap:GuaranteeObligationsMaximumExposure>
<us-gaap:GuaranteeObligationsMaximumExposure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-6">4000000</us-gaap:GuaranteeObligationsMaximumExposure>
<us-gaap:GuaranteeObligationsMaximumExposure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">6800000</us-gaap:GuaranteeObligationsMaximumExposure>
<cycc:GuarantorObligationsModifiedPaymentForWhichPartiesAgreed contextRef="Context_As_Of_22_Jun_2009T00_00_00_TO_22_Jun_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">1700000</cycc:GuarantorObligationsModifiedPaymentForWhichPartiesAgreed>
<cycc:GuarantorObligationsModifiedPaymentForWhichPartiesAgreed contextRef="Context_As_Of_22_Jun_2009T00_00_00_TO_22_Jun_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-6">1000000</cycc:GuarantorObligationsModifiedPaymentForWhichPartiesAgreed>
<cycc:GuarantorObligationsAmountPaid contextRef="Context_As_Of_01_Jul_2009T00_00_00_TO_01_Jul_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">800000</cycc:GuarantorObligationsAmountPaid>
<cycc:GuarantorObligationsAmountPaid contextRef="Context_As_Of_01_Jul_2009T00_00_00_TO_01_Jul_2009T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-5">500000</cycc:GuarantorObligationsAmountPaid>
<cycc:GuarantorObligationsAmountPaid contextRef="Context_As_Of_06_Jan_2010T00_00_00_TO_06_Jan_2010T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">800000</cycc:GuarantorObligationsAmountPaid>
<cycc:GuarantorObligationsAmountPaid contextRef="Context_As_Of_06_Jan_2010T00_00_00_TO_06_Jan_2010T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-5">500000</cycc:GuarantorObligationsAmountPaid>
<cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">6300000</cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels>
<cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-5">3800000</cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels>
<cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="GBP" decimals="-5">3900000</cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels>
<cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="USD" decimals="-5">6600000</cycc:GuarantorObligationsPotentialAmountToBePaidIfStaffingLevelsReducedBelowPrescribedLevels>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="pure" decimals="2">0.30</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<cycc:FairValueAssumptionsProbabilityOfFallingStaffingLevelBelowMinimumPrescribedLevelsWithinPrescribedTimePeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_GuaranteeObligationsByNatureAxis_PerformanceGuaranteeMember" unitRef="pure" decimals="2">0.01</cycc:FairValueAssumptionsProbabilityOfFallingStaffingLevelBelowMinimumPrescribedLevelsWithinPrescribedTimePeriod>
<us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">1744000</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
<us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">1374000</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">427000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">1015000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">357000</us-gaap:GrantsReceivableCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">202000</us-gaap:GrantsReceivableCurrent>
<cycc:SalesTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">209000</cycc:SalesTaxReceivableCurrent>
<cycc:SalesTaxReceivableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">378000</cycc:SalesTaxReceivableCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">132000</us-gaap:DepositsAssetsCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">128000</us-gaap:DepositsAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">519000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">325000</us-gaap:OtherAssetsCurrent>


<cycc:AccruedResearchAndDevelopmentCostsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">3435000</cycc:AccruedResearchAndDevelopmentCostsCurrent>
<cycc:AccruedResearchAndDevelopmentCostsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">2761000</cycc:AccruedResearchAndDevelopmentCostsCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">265000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">183000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">731000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">151000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember_RangeAxis_MaximumMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember_RangeAxis_MinimumMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">74000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">14000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">60000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="-3">146000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">29000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">117000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">183000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">57000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">126000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">370000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">115000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">255000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">949685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1001298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">32697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">487253</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">514045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">15.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">14.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">31.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">4.23</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">23.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P7Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P7Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P9Y4M13D</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P4Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-3">152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-3">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-3">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">1428571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" id="Footnote-1_1">119248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" id="Footnote-1_2">119015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0">85097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="shares" xsi:nil="true" id="Footnote-1_3"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" id="Footnote-1_4">233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="USD_per_Share" decimals="2">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="USD_per_Share" decimals="2">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="USD_per_Share" decimals="2">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember" unitRef="pure" decimals="2">0.00</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.30</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsNumberOfSecuritiesUsedToCalculateWeightedAverageRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="Security" decimals="INF">2</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsNumberOfSecuritiesUsedToCalculateWeightedAverageRiskFreeInterestRate>
<cycc:LicenseAgreementPotentialFutureMilestonePayments contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-6">10000000</cycc:LicenseAgreementPotentialFutureMilestonePayments>
<us-gaap:PreferredStockRedemptionPricePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_PreferredStockRedemptionPeriodAxis_PreferredStockRedemptionPeriodFromYear1November2013To31October2014Member" unitRef="USD_per_Share" decimals="2">10.06</us-gaap:PreferredStockRedemptionPricePerShare>
<us-gaap:PreferredStockRedemptionPricePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_PreferredStockRedemptionPeriodAxis_PreferredStockRedemptionPeriodFromYear1November2014AndThereafterMember" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:PreferredStockLiquidationPreference>
<cycc:PreferredStockConvertibleConversionRatio contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="Conversion_rate" decimals="5">0.06079</cycc:PreferredStockConvertibleConversionRatio>
<cycc:ConvertiblePreferredStockConversionPricePerShare contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">164.50</cycc:ConvertiblePreferredStockConversionPricePerShare>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">20381</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<cycc:NumberOfSeriesOfPreferredStock contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="Series" decimals="INF">1</cycc:NumberOfSeriesOfPreferredStock>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">246.75</us-gaap:SharePrice>
<cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">1.50</cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice>
<cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P20D</cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
<cycc:PreferredStockConversionObligationNumberOfTradingDays contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P30D</cycc:PreferredStockConversionObligationNumberOfTradingDays>
<cycc:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P5D</cycc:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion>
<cycc:PreferredStockNumberOfQuartersInWhichCashDividendsNotPaid contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="Quarter" decimals="INF">6</cycc:PreferredStockNumberOfQuartersInWhichCashDividendsNotPaid>
<cycc:NumberOfBoardOfDirectorsToBeElectedByPreferredStockHoldersUponFailureToPayDividendsOnPreferredStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="Director" decimals="INF">2</cycc:NumberOfBoardOfDirectorsToBeElectedByPreferredStockHoldersUponFailureToPayDividendsOnPreferredStock>
<cycc:NumberOfBoardOfDirectorsElectedByPreferredStockHoldersDueToFailureToPayDividendsOnPreferredStock contextRef="Context_Custom_01_Aug_2010T00_00_00_TO_02_Aug_2010T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="Director" decimals="INF">2</cycc:NumberOfBoardOfDirectorsElectedByPreferredStockHoldersDueToFailureToPayDividendsOnPreferredStock>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<cycc:PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</cycc:PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation>
<us-gaap:DebtInstrumentTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P25Y</us-gaap:DebtInstrumentTerm>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">792460</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Jan_2006T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">1711540</us-gaap:ConversionOfStockSharesConverted1>



<us-gaap:PurchaseObligation contextRef="Context_As_Of_14_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-6">19000000</us-gaap:PurchaseObligation>
<us-gaap:PurchaseObligation contextRef="Context_As_Of_14_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_RangeAxis_MaximumMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="USD" decimals="-6">18000000</us-gaap:PurchaseObligation>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration contextRef="Context_Custom_01_Dec_2012T00_00_00_TO_14_Dec_2012T00_00_00_EquityOfferingComponentsAxis_December2012StockIssuanceMember_LegalEntityAxis_AspireCapitalFundLLCMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">74548</us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_14_Nov_2013T00_00_00_EquityOfferingComponentsAxis_November2013StockIssuanceMember_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_AspireCapitalFundLLCMember" unitRef="shares" decimals="INF">166105</us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration>
<cycc:CommonStockUnderwritingAgreementShares contextRef="Context_As_Of_16_May_2013T00_00_00_TO_16_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="shares" decimals="INF">6666667</cycc:CommonStockUnderwritingAgreementShares>
<us-gaap:EquityIssuancePerShareAmount contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember" unitRef="USD_per_Share" decimals="2">4.53</us-gaap:EquityIssuancePerShareAmount>
<us-gaap:EquityIssuancePerShareAmount contextRef="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="USD_per_Share" decimals="2">3.00</us-gaap:EquityIssuancePerShareAmount>
<us-gaap:EquityIssuancePerShareAmount contextRef="Context_Custom_01_May_2013T00_00_00_TO_21_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="USD_per_Share" decimals="2">3.00</us-gaap:EquityIssuancePerShareAmount>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember" unitRef="shares" decimals="INF">669726</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_May_2013T00_00_00_TO_21_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="shares" decimals="INF">6833334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember" unitRef="shares" decimals="INF">2857143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">31643</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<cycc:NumberOfSharesIssuedDuringPeriodSubjectToUnderwritersOverAllotmentOption contextRef="Context_Custom_01_May_2013T00_00_00_TO_21_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="shares" decimals="INF">166667</cycc:NumberOfSharesIssuedDuringPeriodSubjectToUnderwritersOverAllotmentOption>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_May_2013T00_00_00_TO_21_May_2013T00_00_00_EquityOfferingComponentsAxis_May2013SaleOfCommonStockMember" unitRef="USD" decimals="-6">19000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember" unitRef="USD" decimals="-5">9300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember" unitRef="USD" decimals="-5">2900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<cycc:EquityIssuancePerShareAmountNumberOfDaysUsedToCalculateAverageClosingPrice contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember">P10D</cycc:EquityIssuancePerShareAmountNumberOfDaysUsedToCalculateAverageClosingPrice>
<cycc:EquityIssuanceLockUpPeriod contextRef="Context_Custom_01_Mar_2012T00_00_00_TO_22_Mar_2012T00_00_00_EquityOfferingComponentsAxis_March2012SaleOfCommonStockAndEconomicRightsMember">P1Y</cycc:EquityIssuanceLockUpPeriod>
<cycc:EconomicRightSettledForPayments contextRef="Context_Custom_01_Apr_2013T00_00_00_TO_30_Apr_2013T00_00_00" unitRef="USD" decimals="-5">600000</cycc:EconomicRightSettledForPayments>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">1440022</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2009StockIssuanceMember" unitRef="shares" decimals="INF">98893</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceTwoMember" unitRef="shares" decimals="INF">101785</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceOneMember" unitRef="shares" decimals="INF">100714</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_October2010StockIssuanceMember" unitRef="shares" decimals="INF">594513</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2011StockIssuanceMember" unitRef="shares" decimals="INF">544117</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">12.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2009StockIssuanceMember" unitRef="USD_per_Share" decimals="2">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceTwoMember" unitRef="USD_per_Share" decimals="2">22.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_January2010StockIssuanceOneMember" unitRef="USD_per_Share" decimals="2">19.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_October2010StockIssuanceMember" unitRef="USD_per_Share" decimals="2">13.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_EquityOfferingComponentsAxis_July2011StockIssuanceMember" unitRef="USD_per_Share" decimals="2">9.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">151773</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">24000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">50000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">10000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">23000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
<cycc:DisposalGroupIncludingDiscontinuedOperationShortTermPortionOfMinimumRoyaltyArrangementReceivableNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">379000</cycc:DisposalGroupIncludingDiscontinuedOperationShortTermPortionOfMinimumRoyaltyArrangementReceivableNet>
<cycc:DisposalGroupIncludingDiscontinuedOperationShortTermPortionOfMinimumRoyaltyArrangementReceivableNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">258000</cycc:DisposalGroupIncludingDiscontinuedOperationShortTermPortionOfMinimumRoyaltyArrangementReceivableNet>
<cycc:DisposalGroupIncludingDiscontinuedOperationReturnsIndemnificationReceivableNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">260000</cycc:DisposalGroupIncludingDiscontinuedOperationReturnsIndemnificationReceivableNet>
<cycc:DisposalGroupIncludingDiscontinuedOperationReturnsIndemnificationReceivableNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">145000</cycc:DisposalGroupIncludingDiscontinuedOperationReturnsIndemnificationReceivableNet>
<cycc:DisposalGroupIncludingDiscontinuedOperationLongTermPortionOfMinimumRoyaltyArrangementReceivableNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">72000</cycc:DisposalGroupIncludingDiscontinuedOperationLongTermPortionOfMinimumRoyaltyArrangementReceivableNet>
<cycc:DisposalGroupIncludingDiscontinuedOperationLongTermPortionOfMinimumRoyaltyArrangementReceivableNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">24000</cycc:DisposalGroupIncludingDiscontinuedOperationLongTermPortionOfMinimumRoyaltyArrangementReceivableNet>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">711000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">427000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
<cycc:DisposalGroupIncludingDiscontinuedOperationReturnsProvision contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">260000</cycc:DisposalGroupIncludingDiscontinuedOperationReturnsProvision>
<cycc:DisposalGroupIncludingDiscontinuedOperationReturnsProvision contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ProductPromotionAndSaleOperationMember" unitRef="USD" decimals="-3">145000</cycc:DisposalGroupIncludingDiscontinuedOperationReturnsProvision>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_03_Apr_2014T00_00_00_TO_03_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_EquityOfferingComponentsAxis_April2014IssuanceMember" unitRef="USD_per_Share" decimals="2">3.50</us-gaap:SharesIssuedPricePerShare>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.86</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.46</us-gaap:EarningsPerShareBasic>
<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
<us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.86</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.46</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">13927371</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">11849270</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">22582283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">21064739</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">41929</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember" unitRef="USD" decimals="-3">20000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByLiabilityClassAxis_GuaranteesMember" unitRef="USD" decimals="-3">-20000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1519px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;Six&amp;#160;Months&amp;#160;Ended&lt;br  /&gt;June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 851px; text-align: left;"&gt;Net income (loss) from continuing operations&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 122px; text-align: right;"&gt;1,478&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(4,819&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(1,620&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 121px; text-align: right;"&gt;(9,696&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Deemed dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(8,366&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dividend on convertible exchangeable preferred shares&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(63&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(185&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(100&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Numerator for earnings per share for Income (loss) from continuing operations &amp;#8211; Basic and Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,415&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(4,869&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(10,171&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(9,796&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Weighted average shares of common stock outstanding &amp;#8211; Basic&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13,885,442&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Dilutive effect of stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;41,929&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average shares of common stock outstanding - Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;13,927,371&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;22,582,283&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;11,849,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;21,064,739&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Basic&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net income (loss) from continuing operations &amp;#8211; Diluted&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;0.10&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.22&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.86&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;(0.47&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;
&lt;table style="width: 1365.45px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 8pt;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1174.85px; text-indent: -10pt; padding-left: 10pt;"&gt;Balance as of December&amp;#160;31, 2013&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 136.36px; text-align: right;"&gt;20&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 13.63px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1pt; padding-left: 10pt;"&gt;Change in valuation of Scottish Enterprise agreement&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(20&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 2.5pt; padding-left: 10pt;"&gt;Balance as of June 30, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:OtherLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="-3">241000</us-gaap:OtherLiabilities>
<us-gaap:OtherLiabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-3">238000</us-gaap:OtherLiabilities>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_4" xlink:label="lab_Footnote-1_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_4"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">Includes 85,097 restricted stock units issued that will vest upon the fulfillment of certain clinical and financial conditions.</link:footnote>
</link:footnoteLink>
<xbrli:context id="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">1513653</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<cycc:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesAtStatedConvertibleOption contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">48174</cycc:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesAtStatedConvertibleOption>
<cycc:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesIncrementalShares contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">1465479</cycc:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesIncrementalShares>
<xbrli:context id="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_6ME_01-Jan-2013T00_00_00_TO_30-Jun-2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-5">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Certain amounts in prior period financial statements have been reclassified to conform to current period financial statement presentation. On the consolidated balance sheet as of December 31, 2013, certain amounts have been reclassified from &amp;#8220;Accrued and other current liabilities&amp;#8221; to &amp;#8220;Other liabilities.&amp;#8221;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
</xbrli:xbrl>


